Company Overview and News

4
Cellular Biomedicine Group to Present on Three Panels at B. Riley FBR Annual Healthcare Conference

2018-08-28 globenewswire
SHANGHAI, China and CUPERTINO, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company will present on three panels at the B. Riley FBR Annual Healthcare Conference to be held on September 4, 2018 in New York City, as well as meeting with investors.
TMO CBMG

3
Cellular Biomedicine Group (CBMG) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Cellular Biomedicine Group (CBMG - Free Report) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items.
NRCI NRC ELY SLDA NRCIA OBSV NRCIB CBMG

4
Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights

2018-08-08 globenewswire
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the second quarter and six months ended June 30, 2018.
TMO CBMG

5
Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland

2018-06-22 globenewswire
SHANGHAI, China and CUPERTINO, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the grand opening of a new research and development center in Gaithersburg, Maryland.
TMO CBMG

6
Cellular Biomedicine Group to Present a Keynote Address at CAR-TCR Summit Asia

2018-06-21 globenewswire - 1
SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, will participate in the upcoming CAR-TCR Summit Asia to be held in Singapore, June 27-28, 2018. The Company’s CEO, Tony (Bizuo) Liu, will present a keynote address entitled “Digital Decades Ahead For Biotech” as part of the “Manufacturing Scale Up & Automation” portion of the Summit.
TMO CBMG

1
CBMG / Cellular Biomedicine Group, Inc. null

2018-05-31 sec.gov
Blueprint Cellular Biomedicine Grou
CBMG

1
BRIEF-Cellular Biomedicine Group Qtrly Loss Per Share $0.51

2018-05-08 reuters
* CELLULAR BIOMEDICINE GROUP INC - QTRLY LOSS PER SHARE $0.51 Source text for Eikon: Further company coverage:
CBMG

1
PHI Group Declares Special Stock Dividend and Spins off American Pacific Resources, Inc. Subsidiary

2018-04-25 globenewswire
New York, NY, April 25, 2018 (GLOBE NEWSWIRE) -- PHI Group, Inc., (www.phiglobal.com) (OTCQB:PHIL), a company focused on mergers and acquisitions and investments in natural resources, energy, agriculture and special situations, announced today that American Pacific Resources, Inc. (www.aprgold.com), a wholly owned subsidiary of the Company, will be spun off into its own separate publicly traded entity.
CBMG PHIL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 15117P102